Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
Open Access
- 14 September 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 211 (4), 549-557
- https://doi.org/10.1093/infdis/jiu511
Abstract
Ebolavirus and Marburgvirus cause severe hemorrhagic fever with high mortality and are potential bioterrorism agents. There are no available vaccines or therapeutic agents. Previous clinical trials evaluated transmembrane-deleted and point-mutation Ebolavirus glycoproteins (GPs) in candidate vaccines. Constructs evaluated in this trial encode wild-type (WT) GP from Ebolavirus Zaire and Sudan species and the Marburgvirus Angola strain expressed in a DNA vaccine. The VRC 206 study evaluated the safety and immunogenicity of these DNA vaccines (4 mg administered intramuscularly by Biojector) at weeks 0, 4, and 8, with a homologous boost at or after week 32. Safety evaluations included solicited reactogenicity and coagulation parameters. Primary immune assessment was done by means of GP-specific enzyme-linked immunosorbent assay. The vaccines were well tolerated, with no serious adverse events; 80% of subjects had positive enzyme-linked immunosorbent assay results (≥30) at week 12. The fourth DNA vaccination boosted the immune responses. The investigational Ebolavirus and Marburgvirus WT GP DNA vaccines were safe, well tolerated, and immunogenic in this phase I study. These results will further inform filovirus vaccine research toward a goal of inducing protective immunity by using WT GP antigens in candidate vaccine regimens. NCT00605514.Keywords
This publication has 22 references indexed in Scilit:
- Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in HumansClinical and Vaccine Immunology, 2012
- Ebolavirus vaccines for humans and apesCurrent Opinion in Virology, 2012
- DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trialsThe Lancet Infectious Diseases, 2011
- CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primatesNature Medicine, 2011
- Filovirus emergence and vaccine development: A perspective for health care practitioners in travel medicineTravel Medicine and Infectious Disease, 2011
- A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical TrialThe Journal of Infectious Diseases, 2011
- pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGNJournal of Virology, 2004
- Development of a preventive vaccine for Ebola virus infection in primatesNature, 2000
- Crystal structure of the matrix protein VP40 from Ebola virusThe EMBO Journal, 2000
- Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA virusesJournal of General Virology, 1992